Shares of assisted reproductive services (ARS) company, Virtus Health Ltd (ASX: VRT), have opened up more than 4% higher today after releasing better-than-expected FY16 results.

The company delivered a 14.5% increase in reported net profit after tax (NPAT), which was driven primarily by growth from its international operations.

Other highlights from the result included:

  • Revenue up 11.6% to $261.2 million
  • Total cycles up 9.6% to 18,719
  • Total treatments up 14% to 34,269
  • Reported EBITDA up 12.3% to $68.9 million, adjusted EBITDA up 8.5% to $67.6 million
  • Adjusted EBIT margin decreased 75 bps to 21.6%
  • Reported NPAT increased 14.5% to $34.8 million, adjusted NPAT increased by 5.8% to $34.6 million
  • Diluted earnings per share (EPS) increased 11.6% to 40.79 cents
  • Final dividend of 15 cents per share, bringing the full year dividend to 29 cents per share – an increase of 7.4% from FY15

Overall, this result from Virtus was solid without being spectacular. The Australian division continues to churn out steady growth, albeit at a much lower rate than the international division.

The result was also consistent with Virtus’ recent financial performance, as highlighted by the graphs below:

Source: Company Presentation

Source: Company Presentation

Australian Division

New entrants into the Australian ARS market have resulted in an increase in competition recently, although Virtus was still able to increase Australian cycle numbers by 6.6% to 16,097 cycles and segment EBITDA by 3.8% to $71.2 million. Virtus enjoyed especially strong growth in New South Wales over the year, while growth in Queensland and Tasmania was broadly in line with the overall ARS market.

International Division

The international division enjoyed very strong growth in FY16 with a 46.6% increase in treatment numbers. Operations in Ireland were especially strong and the company’s operations in Singapore have finally become profitable also. Although the result was off a low base, Virtus achieved international EBITDA growth of 138% to $5.7 million.

As highlighted by the chart below, the international division is now beginning to make a substantial contribution to the group’s overall performance.

Source: Company Presentation

Source: Company Presentation

Outlook

Virtus hasn’t provided any guidance to the market but recent trends suggests investors should expect the international operations to continue to be the growth driver behind the company’s overall results. Management has noted that it remains focused on pursuing further expansion opportunities in the UK and Europe and this should provide further growth opportunities moving forward.

Valuation

Virtus shares have increased by around 74% over the past 12 months and this sees the shares currently trade on a trailing price-to-earnings (P/E) ratio of just over 20. The shares are also offering a trailing dividend yield of 3.5%.

Foolish takeaway

A P/E ratio of 20 appears to be quite attractive for a healthcare company operating in a market with attractive demographic and social trends, especially if it can continue to make progress with its overseas expansion strategy.

With that said, the shares have performed exceptionally well over the past 12 months and investors looking for a bargain might want to wait for a pullback before buying a large parcel of shares.

Are you looking to make room in your portfolio for shares like Virtus?

3 Rotten Shares to Sell, and 1 to Buy Today

After a double-digit rally for the ASX since 2016 lows, investors should be on high alert. You'll find a full rundown below of 3 shares we think you should avoid today plus one top pick worth buying, even if the market turns south and the RBA keeps rates at an "emergency low." Simply click here to uncover these stocks.

HOT OFF THE PRESSES: Motley Fool’s #1 Dividend Pick for 2017!

With its shares up 155% in just the last five years, this ‘under the radar’ consumer favourite is both a hot growth stock AND our expert’s #1 dividend pick for 2017. Now we’re pulling back the curtain for you... And all you have to do to discover the name, code and a full analysis is enter your email below!

Simply enter your email now to receive your copy of our brand-new FREE report, “The Motley Fool’s Top Dividend Stock for 2017.”

By clicking this button, you agree to our Terms of Service and Privacy Policy. We will use your email address only to keep you informed about updates to our website and about other products and services we think might interest you. You can unsubscribe from Take Stock at anytime. Please refer to our https://www.fool.com.au/financial-services-guide">Financial Services Guide (FSG) for more information.

Motley Fool contributor Christopher Georges has no position in any stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.